G Paul Amminger
Overview
Explore the profile of G Paul Amminger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
132
Citations
4182
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scott I, Aarts E, Wannan C, Gao C, Clark S, Hartmann S, et al.
Psychol Med
. 2025 Mar;
55:e82.
PMID: 40071550
Background: To improve early intervention and personalise treatment for individuals early on the psychosis continuum, a greater understanding of symptom dynamics is required. We address this by identifying and evaluating...
2.
Wannan C, Scott I, Dwyer D, Clark S, Hartmann S, Ye R, et al.
Schizophr Bull
. 2024 Dec;
PMID: 39707153
Background: Almost 40% of individuals at ultra-high risk (UHR) for psychosis experience persistent attenuated psychotic symptoms (APS) yet it is unclear (1) whether they share overlapping clinical and functional outcomes...
3.
Moller P, Nelson B, McGorry P, Mei C, Amminger G, Yuen H, et al.
Schizophr Bull
. 2024 Sep;
PMID: 39241740
Background: Since the late 1990s, there has been a worldwide surge of scientific interest in the pre-psychotic phase, resulting in the introduction of several clinical tools for early detection. The...
4.
Nelson B, Yuen H, Amminger G, Berger G, Chen E, de Haan L, et al.
Schizophr Bull Open
. 2024 Aug;
3(1):sgaa006.
PMID: 39144772
This study examined whether distress in relation to attenuated psychotic symptoms (DAPS) is associated with clinical outcomes in an ultra-high risk (UHR) for psychosis sample. We also investigated whether DAPS...
5.
Collins M, Bartholomeusz C, Mei C, Kerr M, Spark J, Wallis N, et al.
Psychiatry Res
. 2024 May;
337:115966.
PMID: 38810536
Decreased white matter (WM) integrity and disturbance in fatty acid composition have been reported in individuals at ultra-high risk of psychosis (UHR). The current study is the first to investigate...
6.
Rice S, Nelson B, Amminger G, Francey S, Phillips L, Simmons M, et al.
Early Interv Psychiatry
. 2024 Apr;
18(10):859-868.
PMID: 38600049
Aim: Lithium, even at low doses, appears to offer neuroprotection against a wide variety of insults. In this controlled pilot, we examined the safety (i.e., side-effect profile) of lithium in...
7.
Hartmann S, Cearns M, Pantelis C, Dwyer D, Cavve B, Byrne E, et al.
Biol Psychiatry Cogn Neurosci Neuroimaging
. 2023 Dec;
9(4):417-428.
PMID: 38052267
Background: Multimodal modeling that combines biological and clinical data shows promise in predicting transition to psychosis in individuals who are at ultra-high risk. Individuals who transition to psychosis are known...
8.
Haas S, Ge R, Agartz I, Amminger G, Andreassen O, Bachman P, et al.
JAMA Psychiatry
. 2023 Oct;
81(1):77-88.
PMID: 37819650
Importance: The lack of robust neuroanatomical markers of psychosis risk has been traditionally attributed to heterogeneity. A complementary hypothesis is that variation in neuroanatomical measures in individuals at psychosis risk...
9.
McGorry P, Mei C, Amminger G, Yuen H, Kerr M, Spark J, et al.
JAMA Psychiatry
. 2023 Jun;
80(9):875-885.
PMID: 37378974
Importance: Clinical trials have not established the optimal type, sequence, and duration of interventions for people at ultrahigh risk of psychosis. Objective: To determine the effectiveness of a sequential and...
10.
Amminger G, Rice S, Davey C, Quinn A, Hermens D, Zmicerevska N, et al.
Biol Psychiatry
. 2023 Jun;
95(5):426-433.
PMID: 37355004
Background: Clinical trials suggest that long-chain omega-3 polyunsaturated fatty acids (n-3 PUFAs) (fish oil) may reduce depressive symptoms in adults with major depressive disorder. Therefore, n-3 PUFAs may be a...